CA1341435C - Virus recombinant, du type variole/varicelle/vaccine, servant a immuniser contre des antigenes tumoraux - Google Patents

Virus recombinant, du type variole/varicelle/vaccine, servant a immuniser contre des antigenes tumoraux Download PDF

Info

Publication number: CA1341435C
Authority: CA; Canada
Prior art keywords: oncogene; virus; tumor; proto; pox
Prior art date: 1987-09-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000577071A

Other languages

English (en)

Inventor

Dennis L. Panicali

Rene Bernards

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Pasteur Ltd

US Department of Health and Human Services

Original Assignee

Whitehead Institute for Biomedical Research

Applied Bio Technology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-02

Filing date

1988-09-02

Publication date

2003-07-29

1988-09-02 Application filed by Whitehead Institute for Biomedical Research, Applied Bio Technology Inc filed Critical Whitehead Institute for Biomedical Research

2003-07-29 Application granted granted Critical

2003-07-29 Publication of CA1341435C publication Critical patent/CA1341435C/fr

2020-07-29 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000700605 Viruses Species 0.000 title claims abstract description 130
206010028980 Neoplasm Diseases 0.000 title claims abstract description 92
239000000427 antigen Substances 0.000 title claims abstract description 85
102000036639 antigens Human genes 0.000 title claims abstract description 85
108091007433 antigens Proteins 0.000 title claims abstract description 85
230000003053 immunization Effects 0.000 title claims description 8
238000002649 immunization Methods 0.000 title description 7
210000004027 cell Anatomy 0.000 claims description 87
108090000623 proteins and genes Proteins 0.000 claims description 73
239000013598 vector Substances 0.000 claims description 42
108700020796 Oncogene Proteins 0.000 claims description 41
230000003612 virological effect Effects 0.000 claims description 41
241000700618 Vaccinia virus Species 0.000 claims description 40
108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
206010046865 Vaccinia virus infection Diseases 0.000 claims description 29
208000007089 vaccinia Diseases 0.000 claims description 28
108700020978 Proto-Oncogene Proteins 0.000 claims description 25
102000052575 Proto-Oncogene Human genes 0.000 claims description 25
238000000034 method Methods 0.000 claims description 22
230000010076 replication Effects 0.000 claims description 19
230000006798 recombination Effects 0.000 claims description 17
238000005215 recombination Methods 0.000 claims description 17
230000001413 cellular effect Effects 0.000 claims description 16
241001465754 Metazoa Species 0.000 claims description 13
230000002163 immunogen Effects 0.000 claims description 11
210000002966 serum Anatomy 0.000 claims description 10
102000043276 Oncogene Human genes 0.000 claims description 8
108700020302 erbB-2 Genes Proteins 0.000 claims description 8
230000002246 oncogenic effect Effects 0.000 claims description 6
102000009465 Growth Factor Receptors Human genes 0.000 claims description 5
108010009202 Growth Factor Receptors Proteins 0.000 claims description 5
201000001441 melanoma Diseases 0.000 claims description 5
239000013612 plasmid Substances 0.000 claims description 5
101100118548 Drosophila melanogaster Egfr gene Proteins 0.000 claims description 3
101150111535 trk gene Proteins 0.000 claims description 3
108020003175 receptors Proteins 0.000 claims description 2
102000005962 receptors Human genes 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
102000001253 Protein Kinase Human genes 0.000 claims 4
108060006633 protein kinase Proteins 0.000 claims 4
238000010348 incorporation Methods 0.000 claims 3
101150068332 KIT gene Proteins 0.000 claims 2
230000004075 alteration Effects 0.000 claims 1
210000000628 antibody-producing cell Anatomy 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
230000000869 mutational effect Effects 0.000 claims 1
239000013600 plasmid vector Substances 0.000 claims 1
101150042287 ros gene Proteins 0.000 claims 1
101150029968 rost gene Proteins 0.000 claims 1
230000028993 immune response Effects 0.000 abstract description 9
230000000763 evoking effect Effects 0.000 abstract 1
108020004414 DNA Proteins 0.000 description 40
241000699670 Mus sp. Species 0.000 description 37
101000856426 Mus musculus Cullin-7 Proteins 0.000 description 25
241000700159 Rattus Species 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 21
210000004881 tumor cell Anatomy 0.000 description 15
239000003550 marker Substances 0.000 description 12
238000003780 insertion Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
230000036039 immunity Effects 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
238000010367 cloning Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
101150066555 lacZ gene Proteins 0.000 description 7
230000004044 response Effects 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
101150003725 TK gene Proteins 0.000 description 6
108020004440 Thymidine kinase Proteins 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000010354 integration Effects 0.000 description 6
230000001131 transforming effect Effects 0.000 description 6
229960005486 vaccine Drugs 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
101100501691 Rattus norvegicus Erbb2 gene Proteins 0.000 description 5
102000006601 Thymidine Kinase Human genes 0.000 description 5
230000005809 anti-tumor immunity Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
238000009169 immunotherapy Methods 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
239000006166 lysate Substances 0.000 description 5
238000011603 BDIX rat Methods 0.000 description 4
102000012406 Carcinoembryonic Antigen Human genes 0.000 description 4
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000008076 immune mechanism Effects 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
230000002516 postimmunization Effects 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
230000009466 transformation Effects 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
235000009421 Myristica fragrans Nutrition 0.000 description 3
206010029260 Neuroblastoma Diseases 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000012636 effector Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
102000054766 genetic haplotypes Human genes 0.000 description 3
230000012010 growth Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
239000001115 mace Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
241000283707 Capra Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
102100029974 GTPase HRas Human genes 0.000 description 2
101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
241000726306 Irus Species 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108090000244 Rat Proteins Proteins 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
241000700647 Variola virus Species 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
108020001096 dihydrofolate reductase Proteins 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
230000037433 frameshift Effects 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000010187 selection method Methods 0.000 description 2
241000894007 species Species 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
101150076489 B gene Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000511343 Chondrostoma nasus Species 0.000 description 1
102100031673 Corneodesmosin Human genes 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
102100036654 Dynactin subunit 1 Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101000929626 Homo sapiens Dynactin subunit 1 Proteins 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
235000008694 Humulus lupulus Nutrition 0.000 description 1
244000025221 Humulus lupulus Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
241001091433 Itea Species 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
241000594011 Leuciscus leuciscus Species 0.000 description 1
102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100501690 Mus musculus Erbb2 gene Proteins 0.000 description 1
101100284354 Mus musculus Hr gene Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000011717 athymic nude mouse Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
101150002764 purA gene Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
108700017469 rat Cdkn2c Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
239000011435 rock Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000010451 viral insertion Methods 0.000 description 1
230000001018 virulence Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Immunology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

CA000577071A 1987-09-02 1988-09-02 Virus recombinant, du type variole/varicelle/vaccine, servant a immuniser contre des antigenes tumoraux Expired - Lifetime CA1341435C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9203687A	1987-09-02	1987-09-02
US092,036		1987-09-02

Publications (1)

Publication Number	Publication Date
CA1341435C true CA1341435C (fr)	2003-07-29

Family

ID=22231039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000577071A Expired - Lifetime CA1341435C (fr)	1987-09-02	1988-09-02	Virus recombinant, du type variole/varicelle/vaccine, servant a immuniser contre des antigenes tumoraux

Country Status (2)

Country	Link
CA (1)	CA1341435C (fr)
WO (1)	WO1989001973A2 (fr)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5833975A (en) *	1989-03-08	1998-11-10	Virogenetics Corporation	Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US6241982B1 (en)	1988-03-21	2001-06-05	Chiron Corporation	Method for treating brain cancer with a conditionally lethal gene
US6569679B1 (en)	1988-03-21	2003-05-27	Chiron Corporation	Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
ATE219519T1 (de) *	1989-01-23	2002-07-15	Chiron Corp	Rekombinanttherapien für infektionen und hyperproliferative störungen
ES2106033T3 (es)	1989-05-19	1997-11-01	Genentech Inc	Dominio extracelular de her2.
US7282345B1 (en)	1989-08-04	2007-10-16	Schering Ag	C-erbB-2 external domain: GP75
DE68926248T2 (de) *	1989-09-29	1996-12-19	Oncogene Science Inc	p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
ATE199398T1 (de) *	1989-10-24	2001-03-15	Chiron Corp	Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
CA2040099A1 (fr) *	1990-05-01	1991-11-02	Mariano Barbacid	Tyrosine-kinase-negative trkb
US5759552A (en) *	1991-03-07	1998-06-02	Virogenetics Corporation	Marek's disease virus recombinant poxvirus vaccine
ATE248924T1 (de) *	1991-05-06	2003-09-15	Us Gov Health & Human Serv	Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
DE4205148A1 (de) *	1991-05-25	1993-01-21	Boehringer Mannheim Gmbh	Monoklonale antikoerper gegen c-kit
US5545533A (en) *	1991-05-25	1996-08-13	Boehringer Mannheim Gmbh	Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
ATE152915T1 (de) *	1991-11-29	1997-05-15	Viagene Inc	Immuntherapeutische vektorkonstrukte gegen krebs
CA2158936C (fr)	1993-11-18	2012-02-21	Jack R. Barber	Compositions et procedes d'utilisation de genes a pouvoir letal conditionnel
US5888814A (en) *	1994-06-06	1999-03-30	Chiron Corporation	Recombinant host cells encoding TNF proteins
US6165460A (en) *	1995-07-10	2000-12-26	Therion Biologics Corporation	Generation of immune responses to prostate-specific antigen (PSA)
ES2301178T3 (es)	1996-04-05	2008-06-16	Novartis Vaccines & Diagnostic	Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
WO1998000554A1 (fr)	1996-07-03	1998-01-08	Genetics Institute, Inc.	Protease fmh-1, du type ice/ced
EP1860192A1 (fr)	1996-09-17	2007-11-28	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladies intracellulaires
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
US6261562B1 (en)	1997-02-25	2001-07-17	Corixa Corporation	Compounds for immunotherapy of prostate cancer and methods for their use
WO1999006576A1 (fr)	1997-08-04	1999-02-11	Calydon, Inc.	Sequence stimulatrice de la kallicreine glandulaire chez l'homme, vecteurs comprenant cette sequence et procedes d'utilisation de ces derniers
EP1025212B1 (fr)	1997-10-14	2007-09-26	Darwin Molecular Corporation	Mutants et proteines de fusion de thymidine kinase presentant des activites de thymidine kinase et de guanylate kinase
AU9363798A (en)	1997-11-06	1999-05-31	Chiron S.P.A.	Neisserial antigens
AU2010699A (en)	1997-12-24	1999-07-19	Corixa Corporation	Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
CA2317815A1 (fr)	1998-01-14	1999-07-22	Chiron S.P.A.	Antigenes du $i(neisseria meningitidis)
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AR020318A1 (es)	1998-03-18	2002-05-08	Corixa Corp	Una molecula polinucleotidica aislada, un polipeptido aislado codificado por dicha molecula, un vector de expresion, una celula huesped transformada, unaproteina de fusion, una composicion farmaceutica y una vacuna que comprenden dicho polipeptido o proteina; metodos para el tratamiento, deteccion,
ES2304065T3 (es)	1998-05-01	2008-09-01	Novartis Vaccines And Diagnostics, Inc.	Antigenos y composiciones de neisseria meningitidis.
US6375952B1 (en)	1998-08-07	2002-04-23	University Of Washington	Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
AU1316200A (en)	1998-10-15	2000-05-01	Chiron Corporation	Metastatic breast and colon cancer regulated genes
KR20010084935A (ko) *	1998-11-18	2001-09-07	찰스 굿맨	폴리펩티드
GB2370572B (en) *	1998-11-18	2003-05-07	Oxford Biomedica Ltd	Use of a professional antigen presenting cell
US7148035B1 (en)	1998-11-18	2006-12-12	Oxford Biomedica (Uk) Limited	Polypeptide
JP2002531129A (ja)	1998-12-08	2002-09-24	コリクサコーポレイション	クラミジア感染の処置および診断のための化合物および方法
PT1141331E (pt)	1998-12-16	2008-12-22	Novartis Vaccines & Diagnostic	Quinase dependente de ciclina humana (hpnqalre)
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6911429B2 (en)	1999-04-01	2005-06-28	Transition Therapeutics Inc.	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en)	1999-04-01	2005-03-08	Eva A. Turley	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
CZ20013527A3 (cs)	1999-04-02	2002-10-16	Corixa Corporation	Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
NZ581940A (en)	1999-04-30	2011-07-29	Novartis Vaccines & Diagnostic	Conserved neisserial antigens
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
RU2281956C2 (ru)	1999-10-29	2006-08-20	Чирон С.Р.Л.	Антигенные пептиды neisseria
DK2289545T3 (en)	2000-01-17	2016-09-05	Glaxosmithkline Biologicals Sa	Supplemented OMV vaccine against meningococcus
DK1265915T3 (da)	2000-02-23	2011-02-14	Glaxosmithkline Biolog Sa	Nye forbindelser
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001081379A2 (fr)	2000-04-21	2001-11-01	Corixa Corporation	Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia
DK1284740T3 (da)	2000-05-19	2008-08-04	Corixa Corp	Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
EP1950297A2 (fr)	2000-05-31	2008-07-30	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
PT2133100E (pt)	2000-06-20	2012-01-11	Corixa Corp	Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
AU2001273149A1 (en)	2000-06-28	2002-01-08	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20020165192A1 (en)	2000-09-19	2002-11-07	Kerr William G.	Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en)	2001-09-19	2010-04-06	University Of South Florida	Inhibition of SHIP to enhance stem cell harvest and transplantation
EP2189473A3 (fr)	2000-10-27	2010-08-11	Novartis Vaccines and Diagnostics S.r.l.	Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
CA2433877C (fr)	2001-01-17	2014-11-18	Genecraft, Inc.	Proteines de fusion d'immunoglobuline de domaine de liaison
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
JP4413617B2 (ja)	2001-12-12	2010-02-10	カイロンソチエタアレスポンサビリタリミタータ	Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
CA2860702C (fr)	2001-12-17	2019-02-26	Corixa Corporation	Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
GB0203419D0 (en) *	2002-02-13	2002-04-03	Oxford Biomedica Ltd	Peptide
US20030206916A1 (en)	2002-05-03	2003-11-06	Rush-Presbyterian-St. Luke's Medical Center	Immunogenic peptides
ATE414176T1 (de)	2002-07-18	2008-11-15	Univ Washington	Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
DK2279746T3 (da)	2002-11-15	2013-11-25	Novartis Vaccines & Diagnostic	Overfladeproteiner i neisseria meningitidis
RU2544850C2 (ru)	2003-01-06	2015-03-20	Корикса Корпорейшн	Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
US7812116B2 (en)	2003-07-03	2010-10-12	Rush University Medical Center	Immunogenic peptides
US7807646B1 (en)	2003-11-20	2010-10-05	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en)	2003-11-20	2010-07-27	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
JP4792390B2 (ja)	2004-03-29	2011-10-12	株式会社ガルファーマ	新規ガレクチン９改変体タンパク質及びその用途
EP2199801B1 (fr)	2004-07-14	2013-05-29	The Regents of The University of California	Biomarqueurs pour la détection précoce du cancer des ovaires
CA2579764A1 (fr)	2004-08-10	2006-02-23	Institute For Multiple Myeloma And Bone Cancer Research	Procedes pour reguler la differenciation et traiter le myelome multiple
CN102657855B (zh)	2004-09-22	2015-12-09	葛兰素史密丝克莱恩生物有限公司	用于进行抗葡萄球菌接种的免疫原性组合物
US8846051B2 (en)	2004-10-08	2014-09-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Modulation of replicative fitness by deoptimization of synonymous codons
EP1701165A1 (fr)	2005-03-07	2006-09-13	Johannes Dr. Coy	Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs
JP2008534594A (ja)	2005-03-31	2008-08-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	クラミジア感染に対するワクチン
CA2607715C (fr)	2005-04-29	2015-11-24	Glaxosmithkline Biologicals S.A.	Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
US7462698B2 (en)	2005-07-22	2008-12-09	Y's Therapeutics Co., Ltd.	Anti-CD26 antibodies and methods of use thereof
PT2298815E (pt)	2005-07-25	2015-07-16	Emergent Product Dev Seattle	Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2007047749A1 (fr)	2005-10-18	2007-04-26	Novartis Vaccines And Diagnostics Inc.	Immunisations mucosiques et systemiques avec particules de replicon d’alphavirus
WO2007120368A2 (fr)	2006-01-09	2007-10-25	The Regents Of The University Of California	Combinaisons immunostimulatrices de tnfrsf, tlr, nlr, rhr, du récepteur purinergique et des agonistes du récepteur de la cytokine utilisées pour les vaccins et en immunothérapie anti-tumorale
EP1981905B1 (fr)	2006-01-16	2016-08-31	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Vaccin contre chlamydia
WO2007117657A2 (fr)	2006-04-07	2007-10-18	The Research Foundation Of State University Of New York	Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
MX2008015524A (es)	2006-06-12	2009-01-13	Trubion Pharmaceuticals Inc	Proteinas de union multivalentes monocatenarias con funcion efectora.
PT2486938T (pt)	2006-09-26	2018-06-12	Infectious Disease Res Inst	Composição para vacina contendo adjuvante sintético
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US8673859B2 (en)	2007-03-20	2014-03-18	New York University	GM-CSF cosmeceutical compositions and methods of use thereof
EP3539567A1 (fr)	2007-07-02	2019-09-18	Etubics Corporation	Procédés et compositions permettant de produire un vecteur d'adénovirus destiné à être utilisé avec des vaccinations multiples
EP2274437B1 (fr)	2008-04-10	2015-12-23	Cell Signaling Technology, Inc.	Compositions et procédés pour la détection des mutations d'egfr en cas de cancer
WO2009126944A1 (fr)	2008-04-11	2009-10-15	Trubion Pharmaceuticals, Inc.	Produits d’immunothérapie de cd37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
TWI494125B (zh)	2009-06-05	2015-08-01	Infectious Disease Res Inst	合成的葡萄吡喃糖基脂質佐劑
KR20120129927A (ko)	2010-01-27	2012-11-28	글락소 그룹 리미티드	변형된 투베르쿨로시스 항원
AU2012243039B2 (en)	2011-04-08	2017-07-13	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US10221218B2 (en)	2011-05-10	2019-03-05	The Regents Of The University Of California	Adenovirus isolated from titi monkeys
US9267112B2 (en)	2011-05-10	2016-02-23	The Regents Of The University Of California	Adenovirus isolated from Titi Monkeys
JP2014527398A (ja)	2011-06-21	2014-10-16	オンコファクターコーポレイション	がんの療法および診断のための組成物および方法
AU2012301955A1 (en)	2011-08-29	2014-03-06	The Regents Of The University Of California	Use of HDL-related molecules to treat and prevent proinflammatory conditions
PL2811981T3 (pl)	2012-02-07	2019-09-30	Infectious Disease Research Institute	Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
RU2737765C2 (ru)	2012-05-04	2020-12-02	Пфайзер Инк.	Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
EA034351B1 (ru)	2012-05-16	2020-01-30	Иммьюн Дизайн Корп.	Трехкомпонентная вакцина против впг-2 и способы ее применения
US9605276B2 (en)	2012-08-24	2017-03-28	Etubics Corporation	Replication defective adenovirus vector in vaccination
KR102267292B1 (ko)	2013-03-15	2021-06-21	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	미토콘드리아 유래의 펩티드 ｍｏｔｓ3에 의해 조절되는 물질대사 및 세포 생존
US9428537B2 (en)	2013-03-15	2016-08-30	The Board Of Trustees Of The Leland Stanford Junior University	tRNA derived small RNAs (tsRNAs) involved in cell viability
BR112015025709A2 (pt)	2013-04-18	2017-07-18	Immune Design Corp	monoterapia com gla para uso em tratamento de câncer
CA2909721A1 (fr)	2013-04-19	2014-10-23	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Virus d'amblyomma americanum
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
WO2014210546A1 (fr)	2013-06-27	2014-12-31	University Of Washington Through Its Center For Commercialization	Système polymère biocompatible pour le traitement ciblé de troubles thrombotiques et hémostatiques
EP3016660B1 (fr)	2013-07-01	2020-06-10	The Research Foundation for the State University of New York	Inhibition de ship dans le cadre de la lutte contre l'obésité
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
CA2986354A1 (fr)	2014-06-17	2015-12-30	The Research Foundation For The State University Of New York	Inhibition de ship pour induire l'expression du facteur de stimulation des colonies de granulocytes chez un sujet
EP3594684A1 (fr)	2014-06-27	2020-01-15	Abbott Laboratories	Compositions et procédés pour détecter le pegivirus humain 2 (hpgv-2)
US20180071380A1 (en)	2015-03-20	2018-03-15	The Regents Of The University Of Michigan	Immunogenic compositions for use in vaccination against bordetella
MY197562A (en)	2015-09-21	2023-06-23	Aptevo Res & Development Llc	Cd3 binding polypeptides
WO2017062246A1 (fr)	2015-10-05	2017-04-13	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Souche de rotavirus humain g9p[6] et utilisation comme vaccin
TWI709647B (zh)	2016-01-19	2020-11-11	美商輝瑞股份有限公司	癌症疫苗
US11344619B2 (en)	2016-05-16	2022-05-31	Access To Advanced Health Institute	Formulation containing TLR agonist and methods of use
AU2017273650B2 (en)	2016-06-01	2022-08-18	Access To Advanced Health Institute	Nanoalum particles containing a sizing agent
CA3069363A1 (fr)	2017-07-11	2019-01-17	Pfizer Inc.	Compositions immunogenes comprenant cea muc1 et tert
CN111356477A (zh)	2017-08-01	2020-06-30	Ab工作室有限公司	双特异性抗体及其用途
CA3084394A1 (fr)	2017-11-24	2019-05-31	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-ox40 et leurs utilisations
US11912736B2 (en)	2018-02-21	2024-02-27	The University Of Montana	Diaryl trehalose compounds and uses thereof
CA3091502A1 (fr)	2018-02-23	2019-08-29	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-pd-1 et leurs utilisations
US11572381B2 (en)	2018-03-02	2023-02-07	The University Of Montana	Immunogenic trehalose compounds and uses thereof
CA3105875A1 (fr)	2018-07-20	2020-01-23	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-cd40 et leurs utilisations
JP7387743B2 (ja)	2018-09-12	2023-11-28	ユーカー（ベンジン）バイオファーマカンパニー，リミテッド	抗ｔｎｆｒｓｆ９抗体及びその使用
EP3883969A4 (fr)	2018-11-19	2022-11-16	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anticorps anti-pd-1 et leurs utilisations
JP2022521358A (ja)	2019-02-18	2022-04-06	バイオサイトジェンファーマシューティカルズ（ベイジン）カンパニーリミテッド	ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
AU2020278777A1 (en)	2019-05-23	2021-12-16	The University Of Montana	Vaccine adjuvants based on TLR receptor ligands
KR20230018439A (ko)	2020-06-02	2023-02-07	바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드	공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2188637B (en) *	1986-02-07	1990-11-14	Oncogen	Vaccines against melanoma

1988
- 1988-09-01 WO PCT/US1988/003032 patent/WO1989001973A2/fr unknown
- 1988-09-02 CA CA000577071A patent/CA1341435C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1989001973A3 (fr)	1989-03-23
WO1989001973A2 (fr)	1989-03-09

Legal Events

Date	Code	Title	Description
2020-11-02	MKEX	Expiry	Effective date: 20200831

Publication	Publication Date	Title
CA1341435C (fr)	2003-07-29	Virus recombinant, du type variole/varicelle/vaccine, servant a immuniser contre des antigenes tumoraux
US6699475B1 (en)	2004-03-02	Recombinant pox virus for immunization against tumor-associated antigens
Bernards et al.	1987	Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.
US5242829A (en)	1993-09-07	Recombinant pseudorabies virus
AU606046B2 (en)	1991-01-31	Vaccines against melanoma
EP0652967B1 (fr)	1998-02-04	Particules de virus hybrides a replication defectueuse et auto-assemblees
JP2852515B2 (ja)	1999-02-03	ベクターウイルスおよびベクターウイルスを含む薬用組成物
NZ236294A (en)	1992-05-26	Recombinant vaccines using herpes virus of turkeys against mareks disease; infectious bronchitis; newcastle disease and infectious bursal disease
JPH09511649A (ja)	1997-11-25	免疫不全症組換えポックスウイルス
WO1994017810A1 (fr)	1994-08-18	Vaccin recombine contre le cytomegalovirus
JPH09503902A (ja)	1997-04-22	組み換えウイルス免疫治療
JP2002348255A (ja)	2002-12-04	組換えアビポックスウイルスによる免疫方法
CA2160583A1 (fr)	1994-10-27	Vaccin de type cytomegalovirus recombinant
JP2537345B2 (ja)	1996-09-25	狂犬病に対するワクチン及びその製造法
CA1312837C (fr)	1993-01-19	Vaccin contre la pseudorage
US7645455B2 (en)	2010-01-12	Chimeric lyssavirus nucleic acids and polypeptides
JPH01500161A (ja)	1989-01-26	Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン
EP0831899B1 (fr)	2008-08-13	Compositions a base de poxvirus-calicivirus recombinants et leurs utilisations
WO1997020854A9 (fr)	1998-06-04	Vesicules gazeuses de recombinaison et leur utilisation
AU731706B2 (en)	2001-04-05	Recombinant viral pseudo-particles and vaccinal and antitumoral applications thereof
CA2067469C (fr)	2003-07-01	Vaccin recombinant contre la maladie de marek
US6521236B1 (en)	2003-02-18	Vector vaccine of recombinant feline herpesvirus
US5830477A (en)	1998-11-03	Vaccine against rabies and process for preparation thereof
JP2003230396A (ja)	2003-08-19	ｇｐ３５０／２２０非スプライシング変異体
JPH10512151A (ja)	1998-11-24	Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物